TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Jia Ding und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shanghai Jing'an District Central Hospital, Fudan University, Shanghai, 200040, China. Electronic address: jiading12@…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hedgehog signaling is activated in response to liver injury, and modulates organogenesis. However, the role of non-canonical hedgehog activation via TGF-β1/SMAD3 in hepatic carcinogenesis is poorly understood. TGF-β1/SMAD3-mediated non-canonical activation was found in approximately half of GLI2-positive hepatocellular carcinoma (HCC), and two new GLI2 isoforms with transactivating activity were identified. Phospho-SMAD3 interacted with active GLI2 isoforms to transactivate downstream genes in modulation of stemness, epithelial-mesenchymal transition, chemo-resistance and metastasis in poorly-differentiated hepatoma cells. Non-canonical activation of hedgehog signaling was confirmed in a transgenic HBV-associated HCC mouse model. Inhibition of TGF-β/SMAD3 signaling reduced lung metastasis in a mouse in situ hepatic xenograft model. In another cohort of 55 HCC patients, subjects with high GLI2 expression had a shorter disease-free survival than those with low expression. Moreover, co-positivity of GLI2 with SMAD3 was observed in 87.5% of relapsed HCC patients with high GLI2 expression, indicating an increased risk of post-resection recurrence of HCC. The findings underscore that suppressing the non-canonical hedgehog signaling pathway may confer a potential strategy in the treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Shanghai Jing'an District Central Hospital, Fudan University, Shanghai, 200040, China. Electronic address: jiading12@fudan.edu.cn.
- Department of Medical Microbiology & Parasitology, MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University Shanghai Medical College, Shanghai, 200032, China.
- Department of Hepatobiliary & Pancreatic Surgery, The National Key Clinical Specialty, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361004, China.
- Department of Pathology and Laboratory Medicine, School of Basic Medical Sciences, Fudan University Shanghai Medical College, Shanghai, 200032, China.
- Department of Pathology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361004, China.
- Department of General Surgery, Huashan Hospital of Fudan University, Shanghai, 200041, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ding, J., Yang, Y. Y., Li, P. T., Ma, Y., Zhang, L., Zhou, Y., Jin, C., Li, H. Y., Zhu, Y. F., Liu, X. P., Liu, Z. J., Jia, H. L., Liu, P. G., & Wu, J. (2024). TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216768
Vancouver
Ding J, Yang YY, Li PT, Ma Y, Zhang L, Zhou Y, et al. TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216768
BibTeX
@article{Ding2024,
author = {Ding, Jia and Yang, Yong-Yu and Li, Peng-Tao and Ma, Yue and Zhang, Li and Zhou, Yuan and Jin, Cheng and Li, Hui-Yan and Zhu, Yuan-Fei and Liu, Xiu-Ping and Liu, Zheng-Jin and Jia, Hu-Liang and Liu, Ping-Guo and Wu, Jian},
title = {TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216768}
}
EUVIMED